Answers are grounded in this paper and cite their sources.
Background: Film-forming topical sprays are polymer-based systems that form a thin film after application and may provide localized drug delivery while avoiding some limitations of conventional topical dosage forms. Meloxicam is a non-steroidal anti-inflammatory drug with potential utility in topical delivery. Objective: To formulate Meloxicam-containing film-forming topical spray systems and evaluate their selected physicochemical properties and in-vitro drug release. Methods: Six formulations (F1–F6) were described in the thesis. Preformulation assessment included organoleptic properties, melting point, solubility, UV spectrophotometric analysis, calibration-curve development and FTIR compatibility assessment. Prepared systems were evaluated for appearance, weight uniformity, thickness, folding endurance, drug content and in-vitro release using a Franz diffusion cell with phosphate buffer (pH 6.8) at 37 ± 0.2 °C. Results: Meloxicam showed a reported absorption maximum of 365 nm and an experimental melting-point range of 251–254 °C. The calibration curve was reported as linear over 0–25 µg/mL (r = 0.999). Film weights ranged from 0.123 ± 0.0085 to 0.139 ± 0.0063 g, and thickness ranged from 0.54 ± 0.05 to 0.62 ± 0.05 mm. Drug content ranged from 92.31 ± 0.345% to 97.40 ± 0.425%. F6 was identified by the thesis as the optimized formulation. The reported eight-hour release values ranged from 72.86% to 92.61%, with F1 showing the highest and F6 the lowest release. Conclusion: Meloxicam-containing film-forming systems were prepared and evaluated, and F6 was designated as the optimized batch in the source thesis. Confirmation of formulation composition and the release dataset is required before drawing definitive comparative conclusions.
No takes yet. Share an insight, caveat, or question.
Jeevan Patel (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: